Last reviewed · How we verify
Heterologous boost schedule
A heterologous boost schedule is a vaccination strategy that uses different vaccine platforms or antigens in sequential doses to enhance immune response breadth and durability.
A heterologous boost schedule is a vaccination strategy that uses different vaccine platforms or antigens in sequential doses to enhance immune response breadth and durability. Used for COVID-19 vaccination (heterologous prime-boost regimens), Infectious disease prevention (general application).
At a glance
| Generic name | Heterologous boost schedule |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This approach primes the immune system with one vaccine type (e.g., viral vector or protein subunit) and then boosts with a different platform targeting the same antigen, leveraging complementary immune pathways. This heterologous prime-boost strategy can generate stronger cellular and humoral immunity compared to homologous schedules, particularly useful for infectious disease and cancer vaccines.
Approved indications
- COVID-19 vaccination (heterologous prime-boost regimens)
- Infectious disease prevention (general application)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Immunogenicity of COVID-19 Vaccine on Heterologous Schedule (PHASE2)
- A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults (PHASE4)
- Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines (PHASE2)
- Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines (PHASE3)
- Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) (PHASE2)
- 2013/2017 H7N9 Prime-Boost Interval (PHASE2)
- Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine (PHASE1)
- PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heterologous boost schedule CI brief — competitive landscape report
- Heterologous boost schedule updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI